The Biostatistics Core consists of partial effort from seven doctoral biostatisticians and related support staff to collaborate and consult with other Cancer Center investigators in the design, conduct, and analysis of cancer-related clinical, preclinical, and epidemiologic investigations, and to review proposals for cancerrelated clinical investigations within the context of the Clinical Research Review Committee (CRC). The Biostatistics Core provides consultation and expertise regarding study design (including validity of the overall design, feasibility of meeting objectives, sample size and projection of study duration), recommendations concerning key infrastructure (data management and computer systems support), data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods if required by the project. The general goal of the Biostatistics Core is to insure that study designs, monitoring, and analyses use state-of-the-art methods, and help developmental studies supported by the Center successfully achieve peer reviewed funding. This Core has continued to undergo controlled growth during the recent grant cycle, particularly by adding faculty and staff with bioiriformatics expertise. In addition to being strongly integrated into all Divisions and Programs in the Center, biostatisticians in the Core have important intellectual ties to other professionals in the medical institutions who are engaged in similar activities in other1 disciplines. This diverse environment provides Cancer Center investigators with a strong, broad-based biostatistical expertise that is always accessible. Plans for the future of Biostatistics include continued controlled growth as required to meet the demands placed upon the Core, collaboration in initiatives in information systems to support clinical and basic science research data, and leadership and participation in bioinformatics and analysis of gene expression data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-45
Application #
7726482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
45
Fiscal Year
2007
Total Cost
$317,850
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151

Showing the most recent 10 out of 2393 publications